Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/24459
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Birlie, Belay | - |
dc.contributor.author | BRAEKERS, Roel | - |
dc.contributor.author | AWOKE AYELE, Tadesse | - |
dc.contributor.author | KASIM, Adetayo | - |
dc.contributor.author | SHKEDY, Ziv | - |
dc.date.accessioned | 2017-09-13T14:22:28Z | - |
dc.date.available | 2017-09-13T14:22:28Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | BMC INFECTIOUS DISEASES, 17, p. 1-13 (Art N° 453) | - |
dc.identifier.issn | 1471-2334 | - |
dc.identifier.uri | http://hdl.handle.net/1942/24459 | - |
dc.description.abstract | Background: Highly active antiretroviral therapy (HAART) has shown a dramatic change in controlling the burden of HIV/AIDS. However, the new challenge of HAART is to allow long-term sustainability. Toxicities, comorbidity, pregnancy, and treatment failure, among others, would result in frequent initial HAART regimen change. The aim of this study was to evaluate the durability of first line antiretroviral therapy and to assess the causes of initial highly active antiretroviral therapeutic regimen changes among patients on HAART. Methods: A Hospital based retrospective study was conducted from January 2007 to August 2013 at Jimma University Hospital, Southwest Ethiopia. Data on the prescribed ARV along with start date, switching date, and reason for change was collected. The primary outcome was defined as the time-to-treatment change. We adopted a multi-state survival modeling approach assuming each treatment regimen as state. We estimate the transition probability of patients to move from one regimen to another. Result: A total of 1284 ART naive patients were included in the study. Almost half of the patients (41.2%) changed their treatment during follow up for various reasons; 442 (34.4%) changed once and 86 (6.69%) changed more than once. Toxicity was the most common reason for treatment changes accounting for 48.94% of the changes, followed by comorbidity (New TB) 14.31%. The HAART combinations that were robust to treatment changes were tenofovir (TDF) + lamivudine (3TC) + efavirenz (EFV), tenofovir + lamivudine (3TC) + nevirapine (NVP) and zidovudine (AZT) + lamivudine (3TC) + nevirapine (NVP) with 3.6%, 4.5% and 11% treatment changes, respectively. Conclusion: Moving away from drugs with poor safety profiles, such as stavudine(d4T), could reduce modification rates and this would improve regimen tolerability, while preserving future treatment options. | - |
dc.description.sponsorship | This work was financially supported by Jimma University Inter-university cooperation (IUC-JU) | - |
dc.language.iso | en | - |
dc.publisher | BIOMED CENTRAL LTD | - |
dc.rights | © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. | - |
dc.subject.other | HIV/AIDS; Highly active antiretroviral therapy; Treatment modification; Survial analysis; Multistate models | - |
dc.subject.other | HIV/AIDS; highly active antiretroviral therapy; treatment modification; survial analysis; multistate models | - |
dc.title | Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 13 | - |
dc.identifier.spage | 1 | - |
dc.identifier.volume | 17 | - |
local.format.pages | 13 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Birlie, Belay] Jimma Univ, Dept Stat, Jimma, Ethiopia. [Braekers, Roel; Shkedy, Ziv] Hasselt Univ, I BioStat, Diepenbeek, Belgium. [Awoke, Tadesse] Univ Gondar, Inst Publ Hlth, Gondar, Ethiopia. [Kasim, Adetayo] Univ Durham, Wolfson Res Inst Hlth & Wellbeing, Manchester, Lancs, England. | - |
local.publisher.place | LONDON | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
local.bibliographicCitation.artnr | 453 | - |
local.class | dsPublValOverrule/author_version_not_expected | - |
dc.identifier.doi | 10.1186/s12879-017-2533-3 | - |
dc.identifier.isi | 000404338000001 | - |
item.contributor | Birlie, Belay | - |
item.contributor | BRAEKERS, Roel | - |
item.contributor | AWOKE AYELE, Tadesse | - |
item.contributor | KASIM, Adetayo | - |
item.contributor | SHKEDY, Ziv | - |
item.validation | ecoom 2018 | - |
item.fulltext | With Fulltext | - |
item.accessRights | Open Access | - |
item.fullcitation | Birlie, Belay; BRAEKERS, Roel; AWOKE AYELE, Tadesse; KASIM, Adetayo & SHKEDY, Ziv (2017) Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia. In: BMC INFECTIOUS DISEASES, 17, p. 1-13 (Art N° 453). | - |
crisitem.journal.eissn | 1471-2334 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
birlie 1.pdf | Published version | 1 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
1
checked on Sep 7, 2020
WEB OF SCIENCETM
Citations
8
checked on Oct 12, 2024
Page view(s)
86
checked on Sep 6, 2022
Download(s)
100
checked on Sep 6, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.